Table 1.

MEK/ERK inhibitors and immunotherapy in cancer.

MEK/ERK Member	Inhibitor	Combination with Immunotherapy	Cancer Type
MEK1/2	Trametinib	4-1BB and OX40 agonist antibodies	Breast cancer [19]
	Selumetinib	Anti-EGFR antibody	Lung adenocarcinoma [39]
	G-38963	Anti-PD-L1 antibody	Colon carcinoma [40]
ERK1/2	BVD523	Positive outcomes in patients previously treated with immunotherapy	NRAS-, BRAF V600–, and non–V600 BRAF-mutant solid tumors [29]